D. W. E. Wicker

Panorama Capital LLC (Panorama Capita) is a venture capital firm founded in 1995 by Chris Albinson, Rod Ferguson, Shahan Soghikian and damion wicker. The firm is headquartered in Campbell, California.

Headquartered in Carlstadt, New Jersey and with a development center in Tel Aviv, Israel, Cadent is the leading provider of 3-D digital solutions for the orthodontic and dental industries. The company services thousands of cases each day for a rapidly expanding customer base. Cadent's offerings improve the efficiency and effectiveness of orthodontic and dental treatments while increasing the revenue of dental healthcare providers. The company is backed by a consortium of leading venture capital investors including Apax Partners, Panorama Capital (J.P. Morgan Partners), Pitango Venture Capital, STAR Ventures, and SV Life Sciences.

The New York Academy of Medicine (NYAM) is a leading advocate for innovation in public health. The non-profit company is based in New York, NY and has subsidiaries in the United States. For 176 years, NYAM has been at the forefront of promoting bold changes to the systems that perpetuate health inequities and prevent communities from achieving good health. NYAM's work includes innovative research, programs, and policy initiatives that value community input for maximum impact. NYAM's library is one of the most significant historical libraries in medicine and public health in the nation, with an extensive range of recommended resources available.

Renovo Plc manufactures and distributes pharmaceutical products. The biopharmaceutical company develops novel pharmaceuticals products to prevent and reduce scarring in the skin, cardiovascular system, eye, central nervous system, internal adhesions, ligaments and systemic fibrotic disorders. The company was founded in 2000 and is headquartered in Manchester, United Kingdom.

Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force.

DJO Opco Holdings, Inc. manufactures and supplies surgical and non-surgical products and services that regenerate and repair soft tissues and bones. It markets its products under brand names such as DonJoy, OfficeCare, and ProCare including rigid knee braces and soft goods. The company markets its products to the surgeons, hospitals, physical therapists, athletic trainers, and other health care professionals. The company is headquartered in Vista, CA.

J.P. Morgan Partners LLC is a private equity firm founded in 1984. The firm headquartered located in New York City.